Targeting a specific pathway in neutrophils to treat deep vein thrombosis.
Official title: Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils
Funded at Louis Stokes Cleveland VA Medical Center · NIH-10516085 · Data updated 2026-11-12
This study is testing a new treatment for deep vein thrombosis (DVT) that aims to reduce blood clot formation by targeting certain cells in your body, and it hopes to offer a safer option than current blood thinners that can cause bleeding.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | October 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| NIH project number | 5I01BX003851-04 |
| Project ID | NIH-10516085 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with deep vein thrombosis who may benefit from new therapeutic options.
✕Less likely to help
Patients who do not have deep vein thrombosis or those who are not responsive to anticoagulant therapies may not benefit from this research.
What this research studies
This research aims to develop a new treatment for deep vein thrombosis (DVT) by targeting a specific interaction between coagulation factor FXII and a receptor called uPAR in neutrophils. The approach focuses on reducing the activation of neutrophils, which play a significant role in the formation of blood clots. By using a nanomedicine-based strategy, the researchers hope to prevent harmful processes that contribute to DVT, such as the formation of neutrophil extracellular traps. This innovative method seeks to provide a safer alternative to current anticoagulant therapies that often lead to increased bleeding risks.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for patients suffering from deep vein thrombosis.
How similar studies have gone: While there have been advancements in anticoagulant therapies, this specific approach targeting the FXII-uPAR-pAkt2 axis in neutrophils is novel and has not been extensively tested in prior studies.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Stavrou, Evi X. — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Stavrou, Evi X.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how DVT forms and heals to prevent vein scarring
This NIH grant supports a physician-scientist to study why deep vein clots form and how vein walls get scarred, with the goal of improving long-term outcomes for patients who develop DVT.
-
Oscillatory blood flow and vein valve health to prevent clots
Aimed at understanding how the natural rhythmic blood flow in leg veins protects against clots and whether restoring that flow can prevent dangerous vein clots in hospitalized patients.
-
Local anti-inflammatory therapy to help dissolve clots and prevent vein damage in DVT
Aims to test a local anti-inflammatory treatment to help resolve deep vein clots and reduce long-term vein problems in people with DVT.
-
Neutrophil integrin α9 and blood clots after stroke in aging
This project looks at how a molecule on white blood cells called neutrophil integrin α9 might cause dangerous vein clots after a stroke, especially in older adults.
-
Metabolic tricks to prevent and heal dangerous blood clots in the leg
A study at a university aims to see if shifting how certain blood cells use energy can stop leg clots from forming and help bodies clear clots faster, reducing future complications.
-
Stopping long-term leg damage after deep vein clots by giving anti-inflammatory medicine around the vein
This will try giving anti-inflammatory medicine around the affected vein to lower the chance of long-term swelling, pain, and skin problems after a deep vein clot (DVT).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.